(ACB) Aurora Cannabis - Ratings and Ratios
Exchange: NASDAQ • Country: Canada • Currency: USD • Type: Common Stock • ISIN: CA05156X8843
ACB: Cannabis, Oils, Capsules, Edibles, Extracts, Vapes, CBD
Aurora Cannabis Inc. (NASDAQ:ACB) operates as a diversified cannabis company, focusing on the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. The company functions through two primary segments: Canadian Cannabis and Plant Propagation. Its product portfolio includes medical and consumer cannabis offerings, hemp-derived CBD products, and a wide range of cannabis-based goods such as dried cannabis, oils, capsules, edibles, extracts, and soft gels. These products are designed for various consumption methods, including smoking, vaporizing, and ingestion in forms like oils and capsules. Aurora also provides patient counseling and outreach services, enhancing its commitment to medical cannabis patients.
The companys adult-use cannabis brands, such as Aurora Drift, San Rafael 71, Daily Special, Whistler, Being, and Greybeard, cater to the recreational market, while its CBD brands, including Reliva and KG7, target the health and wellness sector. On the medical side, Aurora boasts a robust portfolio with brands like MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant, underscoring its dedication to providing high-quality medical cannabis products globally.
Aurora Cannabis Inc. was established in 2013 and is headquartered in Edmonton, Canada. The company has made strategic investments in research and development, particularly in extraction technologies, and has expanded its cultivation capabilities. Its focus on innovation, such as pre-roll and vapor products, aligns with evolving consumer preferences. Additionally, Aurora has strengthened its market position through acquisitions, including MedReleaf and CanniMed, enhancing its medical cannabis offerings and global distribution network.
Exchange: NASDAQ
Type: common stock
Country Origin: Canada
GICS Sub Industry: Pharmaceuticals
Last Price: 5.10
SMA 20: 5.55
SMA 50: 4.71
SMA 200: 5.41
ATR: 0.37
P/E: 0.00
P/E Forward: 769.23
P/B: 0.76
P/S: 0.88
RoE: 1.53
3-Month Forecast:
Based on the provided technical and fundamental data, Aurora Cannabis Inc. (ACB) is expected to experience a challenging three months. Technically, the stock is trading below its SMA20 and SMA50, indicating bearish momentum. The ATR of 0.37 suggests moderate volatility, which could lead to price swings. On the fundamental side, the high forward P/E of 769.23 reflects investor expectations for significant growth, though the current P/E of 0 indicates no earnings. The P/B ratio of 0.76 points to undervaluation relative to book value, while the P/S ratio of 0.88 suggests the stock is reasonably priced relative to sales. However, the low RoE of 1.53 raises concerns about profitability. Overall, the stock may face headwinds due to its current position relative to moving averages and mixed fundamental signals.
Additional Sources for ACB Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ACB Stock Overview
Market Cap in USD | 259m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2014-07-11 |
ACB Stock Ratings
Growth 5y | -86.5% |
Fundamental | -28.8% |
Dividend | 0.0% |
Rel. Strength Industry | 51.3 |
Analysts | 3.67/5 |
Fair Price Momentum | 2.47 USD |
Fair Price DCF | - |
ACB Dividends
No Dividends PaidACB Growth Ratios
Growth Correlation 3m | 43.8% |
Growth Correlation 12m | -49.1% |
Growth Correlation 5y | -92.4% |
CAGR 5y | -44.36% |
CAGR/Max DD 5y | -0.45 |
Sharpe Ratio 12m | -1.30 |
Alpha | 38.22 |
Beta | 1.57 |
Volatility | 71.08% |
Current Volume | 497.8k |
Average Volume 20d | 1443.3k |
As of March 15, 2025, the stock is trading at USD 4.41 with a total of 497,822 shares traded.
Over the past week, the price has changed by -7.35%, over one month by -30.11%, over three months by +2.80% and over the past year by +52.60%.
Probably not. Based on ValueRay Fundamental Analyses, Aurora Cannabis (NASDAQ:ACB) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.82 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACB as of March 2025 is 2.47. This means that ACB is currently overvalued and has a potential downside of -43.99%.
Aurora Cannabis has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold ACB.
- Strong Buy: 2
- Buy: 0
- Hold: 4
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ACB Aurora Cannabis will be worth about 2.8 in March 2026. The stock is currently trading at 4.41. This means that the stock has a potential downside of -37.19%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 32.1 | 627.2% |
Analysts Target Price | 32.1 | 627.2% |
ValueRay Target Price | 2.8 | -37.2% |